Q301--NEW – STX Specialized Molecular Residual Disease Testing
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
257-NETWORK CONTRACT OFFICE 17 (36C257)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C25727Q0058
NAICS
621511 - Medical Laboratories
Classification Code
Q301
Additional Details
Documents1
The Department of Veterans Affairs, Network Contracting Office (NCO) 17, based in San Antonio, Texas, has issued a Special Notice regarding its intent to award an Indefinite Delivery Indefinite Quantity (IDIQ) Firm Fixed Price contract for specialized molecular residual disease testing. This procurement is specifically targeted to support VA facilities within VISN 17 (Texas), with ordering locations to be determined through individual task or delivery orders over five ordering periods.
The contract is intended to secure proprietary molecular genetic reference testing services essential for the evaluation and monitoring of transplant patients and cancer residual disease. The scope of services includes two key items: the Signatera Residual Disease Test (MRD) and the Prospera molecular expression transplant assessment test. These tests are identified by CPT Codes 81479 and 81455, with estimated quantities of 35 and 25 units respectively. Both tests are proprietary to Natera, Inc., located in Austin, Texas, and are not available through any other vendor, distributor, or laboratory. Natera is the sole provider, maintaining exclusive methodologies, assays, intellectual property, technology, reagents, and bioinformatics platforms necessary for these services.
The procurement is classified under NAICS Code 621511 (Medical Laboratories), with Product Service Code Q301. The contract is being managed by the 257-Network Contract Office 17 (36C257), a federal office within the Department of Veterans Affairs. The primary point of contact for this notice is Susan Flores, Contract Specialist, who can be reached at [email protected] or (210) 694-6227.
This Special Notice is not a solicitation or a request for competitive quotes. It is issued solely for information and planning purposes. However, interested parties may submit capability statements demonstrating their ability to provide equivalent proprietary testing. Such responses must clearly establish that an alternative test exists and can be delivered with the same proprietary standards. The government will review all responses but retains full discretion regarding whether to compete the requirement. No costs incurred in responding to this notice will be reimbursed.
The period of performance will span five ordering periods, with exact dates to be determined at the time of award. The contract will remain active throughout these periods, ensuring continuity of specialized molecular testing for VA patients in Texas.
Contractors considering this opportunity should note the sole-source nature of the requirement, the proprietary technology involved, and the focus on supporting critical clinical needs for transplant and cancer patients within the VA system. The procurement is governed by federal regulations and is not subject to set-aside requirements or competitive bidding unless a viable alternative is demonstrated.
For further information, contractors are encouraged to review the notice on SAM.gov (Opportunity ID: 39b8226bbde34b448043b515857536d0) and direct any inquiries or capability statements to the designated contract specialist by the specified deadline.